This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Moderna shares are trading lower, possibly as the stocks sells of from recent strength related to a suspected pneumonic plague in Russia.

Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety

Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to

Novavax Shorts on Edge as Russia Plague Fears Spread

Unconfirmed plague fears sent Novavax up 24% in a potential short squeeze, lifting vaccine stocks despite no clear link to its products.

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Novo Nordisk and Pfizer are compared as pharmaceutical giants navigating different challenges. Novo Nordisk boasts superior profitability with a 33% net margin and strong cash flow, but faces pricing pressures and competition in the GLP-1 weight-loss drug market. Pfizer trades at lower valuations and is improving net income through strategic acquisitions in oncology and obesity, though it faces significant patent cliffs through 2030. The article recommends Pfizer as the better buy in 2026 based on its value metrics and improving earnings trajectory.

Ultragenyx Gene Therapy For MPS IIIA Clears EMA Validation, Holds PRIME And Orphan Designations, Will Fall Under EU Joint Clinical Assessment

Evercore ISI Group Maintains In-Line on Ultragenyx Pharmaceutical, Raises Price Target to $18

Evercore ISI Group analyst Liisa Bayko maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a In-Line and raises the price target from $16 to $18.